REKT-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

BitcoinMaxi
2023-10-13

REKT

T2 Biosystems Stock Tumbles 45% After Preliminary Q3 Financial Results and 1-for-100 Reverse Stock Split

T2 Biosystems (NASDAQ:TTOO) stock plunged 45% in premarket trading Friday after the company released its preliminary Q3 financial results and conducted a 1-for-100 reverse stock split.After Thursday m

T2 Biosystems Stock Tumbles 45% After Preliminary Q3 Financial Results and 1-for-100 Reverse Stock Split

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":229966910959616,"tweetId":"229966910959616","gmtCreate":1697186040212,"gmtModify":1697186044321,"author":{"id":3575705860283755,"idStr":"3575705860283755","authorId":3575705860283755,"authorIdStr":"3575705860283755","name":"BitcoinMaxi","avatar":"https://community-static.tradeup.com/news/e4a0d3f31ab627d7ead179da6e16f516","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>REKT</p></body></html>","htmlText":"<html><head></head><body><p>REKT</p></body></html>","text":"REKT","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/229966910959616","repostId":1111243144,"repostType":2,"repost":{"id":"1111243144","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1697185848,"share":"https://www.laohu8.com/m/news/1111243144?lang=&edition=full","pubTime":"2023-10-13 16:30","market":"us","language":"en","title":"T2 Biosystems Stock Tumbles 45% After Preliminary Q3 Financial Results and 1-for-100 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=1111243144","media":"Tiger Newspress","summary":"T2 Biosystems (NASDAQ:TTOO) stock plunged 45% in premarket trading Friday after the company released its preliminary Q3 financial results and conducted a 1-for-100 reverse stock split.After Thursday m","content":"<html><head></head><body><p>T2 Biosystems (NASDAQ:TTOO) stock plunged 45% in premarket trading Friday after the company released its preliminary Q3 financial results and conducted a 1-for-100 reverse stock split.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/865b421e81fb72799448a4c0a4c07a97\" tg-width=\"841\" tg-height=\"622\"/></p><p style=\"text-align: left;\">After Thursday market close, T2 said that Q3 revenue dropped 60% year-over-year to $1.5M, due largely to a $1M reduction in revenue from BARDA. It added that revenue from its sepsis test panel product fell 31% to $1.1M from last year’s quarter, due in part to a $380K backorder.</p><p style=\"text-align: left;\">T2 said that as of Sept. 30, the company had $24.3M in cash and equivalents. It also raised $21.9M in net proceeds from at-the-market, or ATM, sales in Q3 and was able to convert $10M in term-loan debt with CRG Serving LLC to equity.</p><p style=\"text-align: left;\">Looking forward, T2 expects to report Q4 sepsis and related product revenue of $2.4M. Full year sepsis and related product revenue is expected to be $7.5M, down 10% from 2022, due in part to the backorder.</p><p style=\"text-align: left;\">T2 Biosystems CEO John Sperzel said in a statement that the company was taking “aggressive measures” to address the sepsis backorder situation.</p><p style=\"text-align: left;\">T2 plans to release its full Q3 earnings report in November.</p><p style=\"text-align: left;\">The biotech company also announced Thursday that it had submitted an application with the FDA to include the pathogen A. baumannii in its T2Bacteria Panel.</p><p style=\"text-align: left;\">T2’s split-adjusted shares will begin trading on Friday.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>T2 Biosystems Stock Tumbles 45% After Preliminary Q3 Financial Results and 1-for-100 Reverse Stock Split</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nT2 Biosystems Stock Tumbles 45% After Preliminary Q3 Financial Results and 1-for-100 Reverse Stock Split\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2023-10-13 16:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>T2 Biosystems (NASDAQ:TTOO) stock plunged 45% in premarket trading Friday after the company released its preliminary Q3 financial results and conducted a 1-for-100 reverse stock split.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/865b421e81fb72799448a4c0a4c07a97\" tg-width=\"841\" tg-height=\"622\"/></p><p style=\"text-align: left;\">After Thursday market close, T2 said that Q3 revenue dropped 60% year-over-year to $1.5M, due largely to a $1M reduction in revenue from BARDA. It added that revenue from its sepsis test panel product fell 31% to $1.1M from last year’s quarter, due in part to a $380K backorder.</p><p style=\"text-align: left;\">T2 said that as of Sept. 30, the company had $24.3M in cash and equivalents. It also raised $21.9M in net proceeds from at-the-market, or ATM, sales in Q3 and was able to convert $10M in term-loan debt with CRG Serving LLC to equity.</p><p style=\"text-align: left;\">Looking forward, T2 expects to report Q4 sepsis and related product revenue of $2.4M. Full year sepsis and related product revenue is expected to be $7.5M, down 10% from 2022, due in part to the backorder.</p><p style=\"text-align: left;\">T2 Biosystems CEO John Sperzel said in a statement that the company was taking “aggressive measures” to address the sepsis backorder situation.</p><p style=\"text-align: left;\">T2 plans to release its full Q3 earnings report in November.</p><p style=\"text-align: left;\">The biotech company also announced Thursday that it had submitted an application with the FDA to include the pathogen A. baumannii in its T2Bacteria Panel.</p><p style=\"text-align: left;\">T2’s split-adjusted shares will begin trading on Friday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TTOO":"T2 Biosystems"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111243144","content_text":"T2 Biosystems (NASDAQ:TTOO) stock plunged 45% in premarket trading Friday after the company released its preliminary Q3 financial results and conducted a 1-for-100 reverse stock split.After Thursday market close, T2 said that Q3 revenue dropped 60% year-over-year to $1.5M, due largely to a $1M reduction in revenue from BARDA. It added that revenue from its sepsis test panel product fell 31% to $1.1M from last year’s quarter, due in part to a $380K backorder.T2 said that as of Sept. 30, the company had $24.3M in cash and equivalents. It also raised $21.9M in net proceeds from at-the-market, or ATM, sales in Q3 and was able to convert $10M in term-loan debt with CRG Serving LLC to equity.Looking forward, T2 expects to report Q4 sepsis and related product revenue of $2.4M. Full year sepsis and related product revenue is expected to be $7.5M, down 10% from 2022, due in part to the backorder.T2 Biosystems CEO John Sperzel said in a statement that the company was taking “aggressive measures” to address the sepsis backorder situation.T2 plans to release its full Q3 earnings report in November.The biotech company also announced Thursday that it had submitted an application with the FDA to include the pathogen A. baumannii in its T2Bacteria Panel.T2’s split-adjusted shares will begin trading on Friday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":339,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}